<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143087</url>
  </required_header>
  <id_info>
    <org_study_id>TKIs-cml-002</org_study_id>
    <nct_id>NCT04143087</nct_id>
  </id_info>
  <brief_title>Withdrawal or Reduction TKIs in CML-CP</brief_title>
  <official_title>A Multicenter, Open-access Study of CML-CP Patients Treated With Effective TKIs at Least 5 Years and MR4.5(BCR/ABLIS&lt;0.0032%) Maintenance More Than 18 Months Who Treatment With Half TKIs or Discontinue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare MMR on 12 month treated with half TKIs(including imatinib, dasatinib, and nilotinib)
      or TKIs withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Chronic myeloid leukemia-Chronic phase(CML-CP) patients treated with receive effective
           Tyrosine kinase inhibitor -TKI(including imatinib, dasatinib and nilotinib) for more
           than 5 years, and patients with BCR/ABLIS continuous negative in the last 18 months were
           randomly admitted to maintain the original effective TKI by half or stop taking .

        2. Q-pcr detected BCR/ABLIS in peripheral blood once every month, once every two months
           after half a year, and continuously monitored for 12 months.

        3. If the patients detected molecular recurrence (loss of MMR, BCR/ABLIS &gt; 0.1%), the
           original dose of TKI should be administered again.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMR(BCR/ABL IS&lt;0.01) on 12 moth</measure>
    <time_frame>12 moth</time_frame>
    <description>Half dose TKIs or discontinue TKIs treatment</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>MMR on 12 Month</condition>
  <arm_group>
    <arm_group_label>Withdrawal TKIs</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>halve TKIs</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>withdrawal TKIs or halve TKIs</intervention_name>
    <description>Stop TKIs or treated by half TKIs</description>
    <arm_group_label>Withdrawal TKIs</arm_group_label>
    <arm_group_label>halve TKIs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosed CML chronic phase,Age 18-70 years old,gender is not limited
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70 years old, gender is not limited;

          2. Diagnosed CML chronic phase and effective TKI(including imatinib, dasatinib, and
             nilotinib) was continued for more than 5 years

          3. Q-PCR monitored BCR/ABLIS duration &lt; 0.0032% in the last 18 months

          4. Informed consent of the patient or his legal representative

        Exclusion Criteria:

          1. Patients had history of CML-AP or CML-BC

          2. CML patients with previous or current ABL kinase mutations

          3. CML Patients who have received allogeneic hematopoietic stem cell transplantation

          4. CML Patients who have received immunotherapy (except interferon, including car-t and
             other cellular immunotherapy)

          5. Woman who is pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xu na</last_name>
    <phone>18620698390</phone>
    <email>sprenaa@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NanfangH</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xu na, doctor</last_name>
      <phone>18620698390</phone>
      <email>sprenaa@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 26, 2019</study_first_submitted>
  <study_first_submitted_qc>October 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>October 26, 2019</last_update_submitted>
  <last_update_submitted_qc>October 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>xuna</investigator_full_name>
    <investigator_title>Associate chief physician</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

